Literature DB >> 1383929

Enhancement of ribozyme catalytic activity by a contiguous oligodeoxynucleotide (facilitator) and by 2'-O-methylation.

J Goodchild1.   

Abstract

RNA catalysts (ribozymes) designed to cleave sequences unique to viral RNA's might be developed as therapeutics. For this purpose, they would require high catalytic efficiency and resistance to nucleases. Reported here are two approaches that can be used in combination to improve these properties. First, catalytic efficiency can be improved by oligonucleotides (facilitators) that bind to the substrate contiguously with the 3'-end of the ribozyme. Second, 2'-O-methylation of flanking sequences of the ribozyme increases catalytic activity as well as resistance to nucleases. In combination with a facilitator oligodeoxynucleotide, the cleavage rate was increased 20 fold over that of the unmodified ribozyme.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1383929      PMCID: PMC334191          DOI: 10.1093/nar/20.17.4607

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  32 in total

1.  Preformed ribozyme destroys tumour necrosis factor mRNA in human cells.

Authors:  M Sioud; J B Natvig; O Førre
Journal:  J Mol Biol       Date:  1992-02-20       Impact factor: 5.469

2.  Thiophosphate interference experiments locate phosphates important for the hammerhead RNA self-cleavage reaction.

Authors:  D E Ruffner; O C Uhlenbeck
Journal:  Nucleic Acids Res       Date:  1990-10-25       Impact factor: 16.971

3.  The role of a conserved guanosine residue in the hammerhead-type RNA enzyme.

Authors:  O Odai; H Hiroaki; T Sakata; T Tanaka; S Uesugi
Journal:  FEBS Lett       Date:  1990-07-02       Impact factor: 4.124

4.  Self-cleavage of plus and minus RNAs of a virusoid and a structural model for the active sites.

Authors:  A C Forster; R H Symons
Journal:  Cell       Date:  1987-04-24       Impact factor: 41.582

5.  Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus.

Authors:  M A Muesing; D H Smith; C D Cabradilla; C V Benton; L A Lasky; D J Capon
Journal:  Nature       Date:  1985 Feb 7-13       Impact factor: 49.962

6.  Inhibition of rabbit beta-globin synthesis by complementary oligonucleotides: identification of mRNA sites sensitive to inhibition.

Authors:  J Goodchild; E Carroll; J R Greenberg
Journal:  Arch Biochem Biophys       Date:  1988-06       Impact factor: 4.013

7.  2'-O-Methyl polynucleotides as templates for cell-free amino acid incorporation.

Authors:  B E Dunlap; K H Friderici; F Rottman
Journal:  Biochemistry       Date:  1971-06-22       Impact factor: 3.162

8.  Highly efficient chemical synthesis of 2'-O-methyloligoribonucleotides and tetrabiotinylated derivatives; novel probes that are resistant to degradation by RNA or DNA specific nucleases.

Authors:  B S Sproat; A I Lamond; B Beijer; P Neuner; U Ryder
Journal:  Nucleic Acids Res       Date:  1989-05-11       Impact factor: 16.971

9.  Oligoribonucleotide synthesis using T7 RNA polymerase and synthetic DNA templates.

Authors:  J F Milligan; D R Groebe; G W Witherell; O C Uhlenbeck
Journal:  Nucleic Acids Res       Date:  1987-11-11       Impact factor: 16.971

10.  Function of specific 2'-hydroxyl groups of guanosines in a hammerhead ribozyme probed by 2' modifications.

Authors:  D M Williams; W A Pieken; F Eckstein
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-01       Impact factor: 11.205

View more
  12 in total

1.  A general approach for the use of oligonucleotide effectors to regulate the catalysis of RNA-cleaving ribozymes and DNAzymes.

Authors:  Dennis Y Wang; Beatrice H Y Lai; Anat R Feldman; Dipankar Sen
Journal:  Nucleic Acids Res       Date:  2002-04-15       Impact factor: 16.971

2.  Selection of efficient cleavage sites in target RNAs by using a ribozyme expression library.

Authors:  A Lieber; M Strauss
Journal:  Mol Cell Biol       Date:  1995-01       Impact factor: 4.272

Review 3.  Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects.

Authors:  R A Stull; F C Szoka
Journal:  Pharm Res       Date:  1995-04       Impact factor: 4.200

Review 4.  Hammerhead ribozyme kinetics.

Authors:  T K Stage-Zimmermann; O C Uhlenbeck
Journal:  RNA       Date:  1998-08       Impact factor: 4.942

5.  Peptide nucleic acid (PNA) is capable of enhancing hammerhead ribozyme activity with long but not with short RNA substrates.

Authors:  E Jankowsky; G Strunk; B Schwenzer
Journal:  Nucleic Acids Res       Date:  1997-07-15       Impact factor: 16.971

6.  Effects of variations in length of hammerhead ribozyme antisense arms upon the cleavage of longer RNA substrates.

Authors:  M Sioud
Journal:  Nucleic Acids Res       Date:  1997-01-15       Impact factor: 16.971

Review 7.  Inhibition of gene expression with ribozymes.

Authors:  P Marschall; J B Thomson; F Eckstein
Journal:  Cell Mol Neurobiol       Date:  1994-10       Impact factor: 5.046

8.  A circular trans-acting hepatitis delta virus ribozyme.

Authors:  M Puttaraju; A T Perrotta; M D Been
Journal:  Nucleic Acids Res       Date:  1993-09-11       Impact factor: 16.971

9.  Cleavage of full-length beta APP mRNA by hammerhead ribozymes.

Authors:  R B Denman
Journal:  Nucleic Acids Res       Date:  1993-08-25       Impact factor: 16.971

10.  Oligonucleotide facilitators may inhibit or activate a hammerhead ribozyme.

Authors:  E Jankowsky; B Schwenzer
Journal:  Nucleic Acids Res       Date:  1996-02-01       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.